ROCK IMMUNE, INC.

DENVER, CO

OncologybispecificPhase III

What changed

Study registered, no phase assigned: Tele-group Cognitive Behavioural Family Intervention for Individuals With Schizophrenia and Their Families

11mo agoTrial registeredAug 19, 2025Source filing (opens the source filing in a new tab)

Momentum

68no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
NA registered
Sep 1, 2025
Schizophrenia and Related Disorders · NOT_YET_RECRUITING · sponsor: The Hong Kong Polytechnic University · Tele-group Cognitive Behavioural Family Intervention for Individuals With Schizophrenia and Their Families
ClinicalTrials.gov · NCT07121166 (opens the source filing in a new tab)
Trial
Study registered
Aug 4, 2025
Psychiatric Hospitalization · NOT_YET_RECRUITING · sponsor: The Hong Kong Polytechnic University · Optimal Acute Adult Psychiatric In-patient Care in Hong Kong
ClinicalTrials.gov · NCT07097623 (opens the source filing in a new tab)
Grant
R01 · $771k · non-dilutive
Jul 1, 2025
WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MA, DA · NIA · award ends Mar 31, 2030 · Neuroimage-genomic fingerprints for subtyping and prediction of Alzheimer's Disease and related dementia
NIH RePORTER · NIH RePORTER 11135910 (opens the source filing in a new tab)
Grant
R35 · $1.1M · non-dilutive
Feb 1, 2025
UNIVERSITY OF ILLINOIS AT CHICAGO · PI WANG, ZAIJIE JIM · NHLBI · award ends Jan 31, 2032 · Molecular Mechanism and Targeting of Chronic Pain in Sickle Cell Disease
NIH RePORTER · NIH RePORTER 11036843 (opens the source filing in a new tab)
Grant
R01 · $670k · non-dilutive
Jun 1, 2024
UNIVERSITY OF FLORIDA · PI WANG, ZHENG · NIA · award ends Feb 28, 2029 · Quantification of the neurocognitive, brain, and blood markers of dementia in middle-aged autistic adults
NIH RePORTER · NIH RePORTER 11093338 (opens the source filing in a new tab)
Grant
R01 · $475k · non-dilutive
Mar 1, 2023
UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, ZHOU · NIDDK · award ends Feb 28, 2027 · Role of E-Cadherin Down-Regulation in Prostatic Inflammation and Lower Urinary Tract Dysfunction
NIH RePORTER · NIH RePORTER 11042230 (opens the source filing in a new tab)
Grant
R01 · $452k · non-dilutive
Aug 15, 2022
VANDERBILT UNIVERSITY MEDICAL CENTER · PI YAN, XINQIANG · NIBIB · award ends May 31, 2027 · Integrated Next-generation RF Transmit, Receive and B0 shimming coil system for brain and spinal cord MRI at 7 Tesla
NIH RePORTER · NIH RePORTER 11116987 (opens the source filing in a new tab)
Grant
R01 · $343k · non-dilutive
Jul 6, 2022
YALE UNIVERSITY · PI YAN, XITING · NLM · award ends Mar 31, 2027 · Graph Learning of Cell-cell Communications in Spatial Transcriptomics
NIH RePORTER · NIH RePORTER 11074133 (opens the source filing in a new tab)
Grant
R42 · $248k · non-dilutive
Aug 1, 2021
ROCK IMMUNE, INC. · PI WANG, ZHIRUI · NCI · award ends Jan 31, 2027 · CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
NIH RePORTER · NIH RePORTER 10850989 (opens the source filing in a new tab)
Grant
R01 · $398k · non-dilutive
Mar 4, 2021
METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, ZHIHUI · NCI · award ends Feb 28, 2027 · Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer
NIH RePORTER · NIH RePORTER 11045760 (opens the source filing in a new tab)
Grant
R01 · $640k · non-dilutive
Jan 15, 2019
CLEVELAND CLINIC LERNER COM-CWRU · PI WANG, ZHONG IRENE · NINDS · award ends Mar 31, 2030 · MR Fingerprinting for Epilepsy
NIH RePORTER · NIH RePORTER 11072313 (opens the source filing in a new tab)
Trial
PHASE3 registered
Oct 3, 2016
Oropharynx Cancer · COMPLETED · sponsor: Mayo Clinic · Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
ClinicalTrials.gov · NCT02908477 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator WANG, ZAIJIE JIM is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the grant record at 0.28{"reasons":["no candidate cleared the review threshold"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: Tele-group Cognitive Behavioural Family Intervention for Individuals With Schizophrenia and Their Families
11mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Optimal Acute Adult Psychiatric In-patient Care in Hong Kong
11mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Neuroimage-genomic fingerprints for subtyping and prediction of Alzheimer's Disease and related dementia
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Integrated Next-generation RF Transmit, Receive and B0 shimming coil system for brain and spinal cord MRI at 7 Tesla
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Role of E-Cadherin Down-Regulation in Prostatic Inflammation and Lower Urinary Tract Dysfunction
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · MR Fingerprinting for Epilepsy
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Graph Learning of Cell-cell Communications in Spatial Transcriptomics
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Quantification of the neurocognitive, brain, and blood markers of dementia in middle-aged autistic adults
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R42 · $0.2M · CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
Mar 2025Grant renewalSource (opens the source filing in a new tab)
Phase III trial registered: Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
Feb 2025Trial completedSource (opens the source filing in a new tab)
NIH R35 · $1.1M · Molecular Mechanism and Targeting of Chronic Pain in Sickle Cell Disease
Jan 2025New grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

NA registered

Study registered

R01 · $771k · non-dilutive

R35 · $1.1M · non-dilutive

R01 · $670k · non-dilutive

R01 · $475k · non-dilutive

R01 · $452k · non-dilutive

R01 · $343k · non-dilutive

R42 · $248k · non-dilutive

R01 · $398k · non-dilutive

R01 · $640k · non-dilutive

PHASE3 registered